GLSHQ (Gelesis Holdings) Other Current Payables: $0.00 Mil (As of Jun. 2023)


What is Gelesis Holdings Other Current Payables?

Gelesis Holdings GLSHQ -99.00% Other Current Payables is $0.00 Mil as of Jun. 2023.

Gelesis Holdings's Other Current Payables for the quarter that ended in Jun. 2023 was $0.00 Mil.

Gelesis Holdings Other Current Payables Related Terms

Gelesis Holdings Other Current Payables Historical Data

* Premium members only.

The historical data trend for Gelesis Holdings's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelesis Holdings Other Current Payables Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
Other Current Payables
0.00 0.00

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00

Gelesis Holdings Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.00 Mil mean?
Gelesis Holdings (GLSHQ) has a Other Current Payables of $0.00 Mil as of Jun. 2023. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Gelesis Holdings and its competitors.
Is Gelesis Holdings' Other Current Payables too high?
Gelesis Holdings' current Other Current Payables is $0.00 Mil.
How does Gelesis Holdings' Other Current Payables compare to RBSH and PPCB?
Gelesis Holdings' Other Current Payables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Gelesis Holdings and its competitors. Gelesis Holdings's current Other Current Payables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelesis Holdings stock overvalued right now?
Gelesis Holdings (GLSHQ) has a current Other Current Payables of $0.00 Mil. The current Other Current Payables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Gelesis Holdings (GLSHQ), the current Other Current Payables is $0.00 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelesis Holdings Business Description

Address 501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.